British success story Medopad sets sights on US health tech market

  • 12 July 2018
British success story Medopad sets sights on US health tech market

British healthtech start-up Medopad has announced that it is expanding across the Atlantic following a whirlwind success story in the UK.

The company is to set up shop at Johnson & Johnson’s new New York offices after experiencing a 400% year-on-year growth in project value, which has included deals with The Royal Free, Guys and St Thomas’, GSK, Johnson & Johnson and Boston Scientific.

As part of the move, Medopad said it planned to hire “top healthtech talent” as it sets its sights on conquering the US.

The firm said New York presented “an ideal launch pad” into the US market, citing it as “an established nucleus for the life sciences industry”.

Dan Vahdat, CEO of Medopad, said: “We are thrilled to open a base in the USA as part of Johnson & Johnson’s incubator platform JLABS. This is a fantastic opportunity for Medopad as our values and vision are aligned with J&J’s leadership to help create a world where people can live longer.”

Medopad was recently invited to join Pfizer UK’s London accelerator programme after being recognised for its works in patient monitoring and data analytics technologies.

In January this year, the company signed a Memorandum of Understanding (MoU) with Johns Hopkins University to explore new healthcare solutions using machine learning and patient monitoring solutions.

“We have been working in partnership with US pharmaceuticals, healthcare providers and academic institutions such as Johns Hopkins where Medopad is used to connect clinicians to patients remotely and collect real world evidence,” said Vahdat.

“We look forward to strengthening these bonds and driving more innovative change for better health outcomes for people. The remote patient monitoring market is more than eight times bigger in the US vs UK.”

Subscribe to our newsletter

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Sign up

Related News

ivWatch uses algorithm to reduce injuries from faulty intravenous lines 

ivWatch uses algorithm to reduce injuries from faulty intravenous lines 

Extravasation can cause serious and sometimes lasting injuries. An American company, ivWatch, is piloting a product to lessen the risk. 
AnalystX confirmed as Digital Health’s new strategic event partner 

AnalystX confirmed as Digital Health’s new strategic event partner 

AnalystX and Digital Health have today teamed up as strategic event partners to help shape the data and AI landscape in the health and care.…
AI and Data to look at use of data analytics to address long-term conditions 

AI and Data to look at use of data analytics to address long-term conditions 

A session on Day Two of Digital Health AI and Data will focus on how AI can meet the challenges faced by patients with multiple long-term…

4 Comments

  • I see a lot of buzzwords about this whirlwind success but 0 explanation of what that success is and what Medopad do? Could anyone explain? Their website doesn’t offer much either!

  • What do GSTT use it for?

    • Patient monitoring for dvt I believe

      • Well you’ve done much more important work than that this week. Joining large information systems in two hospitals and linking them to a large shared care record. Perhaps DigitalHealth will come to interview you.

Comments are closed.